Interview with Jan Egberts, CEO, OctoPlus N.V.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Address: Zernikedreef 12, 2333 CL Leiden,Netherlands
Tel: +31 (0)71 524 40 44
OctoPlus is a product-oriented drug delivery company focused on the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. Since our inception in 1995, we have established a successful track record and maintain partnerships with large and small biotech and pharma companies throughout the world.
Our business activities include formulation development services, drug delivery technologies and controlled release product development.
OctoPlus uses its proprietary drug delivery technologies to develop controlled release products for clients.
OctoPlus has developed a number of proprietary drug delivery technologies that facilitate the controlled release of biologically active compounds. Our three main technology platforms enable us to develop tailor-made controlled release formulations for all classes of injectable drug compounds:
OctoDEX®: a dextran-based microsphere delivery technology for proteins and particulate systems.
PolyActive®: a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules.
SynBiosys™: a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules (in collaboration with Innocore BV).
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences…
The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was…
“Two traditions one vision” was the phrase used to describe the 2005 merger that formed Daiichi Sankyo as it is today. While referring specifically to a corporate merger, its message…
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen,…
In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines…
See our Cookie Privacy Policy Here
